This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Bupropion and Restless Legs Syndrome

This study has been completed.
Information provided by (Responsible Party):
Max Bayard, East Tennessee State University Identifier:
First received: February 12, 2008
Last updated: April 4, 2012
Last verified: April 2012
The purpose of this study is to determine if bupropion will improve the symptoms of restless legs syndrome (RLS).

Condition Intervention Phase
Restless Legs Syndrome Drug: Bupropion Drug: Placebo Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Bupropion and Restless Legs Syndrome

Resource links provided by NLM:

Further study details as provided by Max Bayard, East Tennessee State University:

Primary Outcome Measures:
  • Change in International Restless Legs Syndrome Study Group (IRLSSG) Severity Scale. [ Time Frame: Baseline, three weeks, and six weeks ]
    Scale ranges from 0 to 40 points with higher scores being associated with more severe symptoms of restless legs syndrome. There are 10 questions, with points of 0 to 4 per question. The change in IRLSSG score from baseline is recorded at three and six weeks.

  • Clinical Global Impression - Improvement Scale [ Time Frame: three weeks and six weeks ]
  • Ordinal Scale(i.e., 1-8)of Symptom Severity [ Time Frame: three weeks and six weeks ]

Enrollment: 60
Study Start Date: February 2008
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Participants will receive 150MG Bupropion nightly.
Drug: Bupropion
Partipants will receive 150 mg bupropion per night
Other Name: Wellbutrin
Placebo Comparator: 2
Participants will receive matching placebo capsule nightly.
Drug: Placebo
1 capsule nightly for six weeks

Detailed Description:
Adult patients with moderate to severe RLS will be recruited for the study. Those on medications which treat RLS will be asked to discontinue the medications for two weeks prior to beginning the study. All participants will be screened with Beck Depression Inventory, International Restless Legs Syndrome Study Group (IRLSSG) severity scale, and Clinical Global Impression of Improvement (CGI-I) scale. An ordinal scale (i.e. rate symptoms from 1-8) will also be obtained. Participants will be randomized to a placebo or medication group. Those in the medication group will be given 150 mg of bupropion at night for six weeks. Others will receive similar-appearing placebo. Participants will be called at the end of weeks one, two, four and five to assess symptom severity based on IRLSSG scale, and to determine if they are experiencing any adverse effects. At three weeks and six weeks, participants will return to the clinic to complete all four of the initial forms, the Beck Depression Inventory, IRLSSG severity scale, ordinal scale, and CGI-I.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • clinical diagnosis of Restless Legs Syndrome
  • Severity Scale score 15 or higher

Exclusion Criteria:

  • History of seizures
  • History of alcohol use greater than 2 drinks per day or occasional binges of 5 or more drinks per day
  • Suicidal thoughts/ideations
  • Inability to return for follow up appointments at 3 and 6 weeks
  • Lack of access to telephone
  • Eating disorder
  • Age less than 18
  • Pregnancy
  • Unwillingness or inability to discontinue any RLS medications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00621517

United States, Tennessee
East Tennessee State University
Johnson City, Tennessee, United States, 37614
Sponsors and Collaborators
East Tennessee State University
  More Information

Responsible Party: Max Bayard, Associate Professor of Family Medicine, East Tennessee State University Identifier: NCT00621517     History of Changes
Other Study ID Numbers: ETSU-07-061f
Study First Received: February 12, 2008
Results First Received: March 4, 2012
Last Updated: April 4, 2012

Keywords provided by Max Bayard, East Tennessee State University:
Restless Legs Syndrome

Additional relevant MeSH terms:
Psychomotor Agitation
Restless Legs Syndrome
Pathologic Processes
Neurologic Manifestations
Nervous System Diseases
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Mental Disorders
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors processed this record on June 22, 2017